Skip to content
OpenCapital
Get started

Iovance Biotherapeutics, Inc. IOVA D&A

D&A at other companies

Biogen logo
BiogenBIIB
——

Segments

By segment

See full
Single Reportable$8.54M+5.9%

Other financials

Income statement

See full
Revenue$71.4M+44.8%
Gross profit$28.9M+338%
Operating income-$81.0M+33.1%
Net income-$79.0M+32.0%
EPS (diluted)-$0.19+47.2%

Balance sheet

See full
Cash & equivalents$196.5M+14.5%
Total debt$46.8M-11.3%
Total equity$721.8M-6.0%
Total assets$925.7M-4.2%

Cash flow

See full
Operating cash flow-$72.1M+30.5%
CapEx$6.6M+6.4%
Free cash flow-$78.7M+28.4%

Valuation

See full
Market cap$1.9B+32.4%

Profitability

See full
Gross margin36.7%+4.1pp
Operating margin-127.2%-31.0pp
Net margin-123.9%-28.4pp
FCF margin-106.8%-27.5pp

Returns & leverage

See full
Return on equity-47.5%-3.7pp
Debt / equity0.1×0.0×
Current ratio3.6×-0.6×

Where this comes from

Reported directly by Iovance Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.

The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Iovance Biotherapeutics, Inc.'s d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Iovance Biotherapeutics, Inc.'s D&A?
Iovance Biotherapeutics, Inc. (IOVA) reported D&A of $8.54M in Q1 2026.
How has Iovance Biotherapeutics, Inc.'s D&A changed year-over-year?
Iovance Biotherapeutics, Inc.'s D&A increased by 5.9% year-over-year, from $8.07M to $8.54M.
What is the long-term trend for Iovance Biotherapeutics, Inc.'s D&A?
Over 4 years (2021 to 2025), Iovance Biotherapeutics, Inc.'s D&A has grown at a 84.4% compound annual growth rate (CAGR), from $3.11M to $35.94M.
What does D&A mean?
Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.